Today’s cyclodextrin
Reading this paper from Yeungnam University by Jong Oh Kim et al reminded me about a core application of CD’s: improving oral bioavailability of compounds. While this feature does not work generally on all compounds, it certainly does on the ones, where the poor solubility is the main cause of the low oral bioavailability. On the other hand, this feature of CD’s often make developing generic drugs with this excipients impossible, while creating improved/added value reformulations of repurposed APIs remains a target use.
If you have projects like this on your table, you might find it useful to check this website: Development of abiraterone acetate tablets with enhanced oral bioavailability | Journal of Pharmaceutical Investigation (springer.com)
